TREM2, a myeloid cell receptor strongly implicated in AD GWAS, is the target of multiple AD pharmacotherapies, including activating monoclonal antibodies AL002 (Alector) and VHB937 (Novartis), as well as small molecule agonists such as VG-3927 (Vigil Neurosciences). This evidence concerns the gene TREM2 and Alzheimer disease.